Omada Health was founded in 2011 by Adrian James, Andrew Di Michele, and Sean Duffy. CEO Duffy told Bloomberg in 2022 that while he intends to eventually take the company public, he "plans to stay independent for now...Especially given the current state of the public markets." Duffy added that "I tell the company that our job here is to make sure that when we make that flip to public it doesn’t feel like we’re doing anything differently." These comments should not be interpreted to mean that the company is formally pursuing or foregoing an IPO.
Omada Health is a digital health firm that uses virtual consultations and monitoring devices to provide remote care for patients who suffer from chronic illness. In 2020 the company acquired Physera, a telehealth provider that specializes in musculoskeletal care. Omada Health has raised more than $440 million in venture capital funding from investors including Fidelity Management & Research Company, aMoon, Perceptive Advisors, Wellington Management, and Civilization Ventures. A $192 million Series E funding round brought the company's post-money valuation to more than $1 billion.
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
02/23/2022 | Series E | $192MM | $xx.xx | $102.28B | Amoon, Civilization Ventures, Fidelity, Perceptive Advisors, Wellington Management | |
Price per Share
$xx.xx
Shares Outstanding
32,025,620
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Amoon, Civilization Ventures, Fidelity, Perceptive Advisors, Wellington Management
|
||||||
03/16/2021 | Series D-1 | $27MM | $xx.xx | $78.08B | Undisclosed Investors | |
Price per Share
$xx.xx
Shares Outstanding
4,503,601
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Undisclosed Investors
|
||||||
05/19/2020 | Series D | $112.47MM | $xx.xx | $61.29B | Andreessen Horowitz, Cigna Ventures, Civilization Ventures, Kaiser Permanente Ventures, Norwest Venture Partners, Perceptive Advisors, Providence Ventures, Sanofi-Genzyme Bioventures, Us Venture Partners, Wellington Management | |
Price per Share
$xx.xx
Shares Outstanding
22,330,212
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Andreessen Horowitz, Cigna Ventures, Civilization Ventures, Kaiser Permanente Ventures, Norwest Venture Partners, Perceptive Advisors, Providence Ventures, Sanofi-Genzyme Bioventures, Us Venture Partners, Wellington Management
|
||||||
05/10/2017 | Series C-1 | $49.99MM | $xx.xx | $32.02B | Andreessen Horowitz, Cigna, Civilization Ventures, Drx Capital, Ge Ventures, Humana, Kaiser Permanente Ventures, Norwest Venture Partners, Providence Ventures, Sanofi Genzyme Bioventures, U.S. Venture Partners | |
Price per Share
$xx.xx
Shares Outstanding
13,357,797
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Andreessen Horowitz, Cigna, Civilization Ventures, Drx Capital, Ge Ventures, Humana, Kaiser Permanente Ventures, Norwest Venture Partners, Providence Ventures, Sanofi Genzyme Bioventures, U.S. Venture Partners
|
||||||
10/01/2015 | Series C | $48.67MM | $xx.xx | $21.64B | Andreessen Horowitz, Designer Fund, Drx Capital, Ge Ventures, Humana Ventures, Ideo Futures, Norwest Venture Partners, Providence Ventures, Rock Health, Us Venture Partners | |
Price per Share
$xx.xx
Shares Outstanding
15,385,707
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Andreessen Horowitz, Designer Fund, Drx Capital, Ge Ventures, Humana Ventures, Ideo Futures, Norwest Venture Partners, Providence Ventures, Rock Health, Us Venture Partners
|
||||||
04/09/2014 | Series B | $23.33MM | $xx.xx | $6.06B | Andreessen Horowitz, Kaiser Permanente Ventures, The Vertical Group, U.S. Venture Partners | |
Price per Share
$xx.xx
Shares Outstanding
19,724,378
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Andreessen Horowitz, Kaiser Permanente Ventures, The Vertical Group, U.S. Venture Partners
|
||||||
03/21/2013 | Series A | $6.43MM | $xx.xx | $1.61B | Founder Collective, Healthtech Capital, Kapor Capital, New Enterprise Associates, The Vertical Group, Triplepoint Capital, U.S. Venture Partners | |
Price per Share
$xx.xx
Shares Outstanding
12,027,426
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Founder Collective, Healthtech Capital, Kapor Capital, New Enterprise Associates, The Vertical Group, Triplepoint Capital, U.S. Venture Partners
|